Analysis of carboxylesterase 2 transcript variants in cynomolgus macaque liver.


Journal

Xenobiotica; the fate of foreign compounds in biological systems
ISSN: 1366-5928
Titre abrégé: Xenobiotica
Pays: England
ID NLM: 1306665

Informations de publication

Date de publication:
Feb 2019
Historique:
pubmed: 1 2 2018
medline: 6 3 2019
entrez: 1 2 2018
Statut: ppublish

Résumé

Carboxylesterase (CES) is important for the detoxification of a wide range of drugs and xenobiotics. In this study, the hepatic level of CES2 mRNA was examined in cynomolgus macaques used widely in preclinical studies for drug metabolism. Three CES2 mRNAs were present in cynomolgus macaque liver. The mRNA level was highest for cynomolgus CES2A (formerly CES2v3), much lower for cynomolgus CES2B (formerly CES2v1) and extremely low for cynomolgus CES2C (formerly CES2v2). Most various transcript variants produced from cynomolgus CES2B gene did not contain a complete coding region. Thus, CES2A is the major CES2 enzyme in cynomolgus liver. A new transcript variant of CES2A, CES2Av2, was identified. CES2Av2 contained exon 3 region different from wild-type (CES2Av1). In cynomolgus macaques expressing only CES2Av2 transcript, CES2A contained the sequence of CES2B in exon 3 and vicinity, probably due to gene conversion. On genotyping, this CES2Av2 allele was prevalent in Indochinese cynomolgus macaques, but not in Indonesian cynomolgus or rhesus macaques. CES2Av2 recombinant protein showed similar activity to CES2Av1 protein for several substrates. It is concluded that CES2A is the major cynomolgus hepatic CES2, and new transcript variant, CES2Av2, has similar functions to CES2Av1.

Identifiants

pubmed: 29384423
doi: 10.1080/00498254.2018.1435927
doi:

Substances chimiques

RNA, Messenger 0
Carboxylesterase EC 3.1.1.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

247-255

Auteurs

Yasuhiro Uno (Y)

a Shin Nippon Biomedical Laboratories, Ltd , Kainan , Japan.

Yoshiyuki Igawa (Y)

b Graduate School of Pharmaceutical Sciences , Kumamoto University , Kumamoto , Japan.
c Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd , Shinagawa , Japan.

Maori Tanaka (M)

b Graduate School of Pharmaceutical Sciences , Kumamoto University , Kumamoto , Japan.

Kayoko Ohura (K)

b Graduate School of Pharmaceutical Sciences , Kumamoto University , Kumamoto , Japan.

Masakiyo Hosokawa (M)

d Laboratory of Drug Metabolism and Biopharmaceutics, Faculty of Pharmaceutical Sciences , Chiba Institute of Science , Choshi , Japan.

Teruko Imai (T)

b Graduate School of Pharmaceutical Sciences , Kumamoto University , Kumamoto , Japan.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH